Halozyme Therapeutics CEO Helen Torley's 2021 pay rises 14% to $7.5M
Halozyme Therapeutics reports 2021 executive compensation
By ExecPay News
Published: March 25, 2022
Halozyme Therapeutics reported fiscal year 2021 executive compensation information on March 25, 2022.
In 2021, four executives at Halozyme Therapeutics received on average a compensation package of $3.7M, a 33% increase compared to previous year.
Average pay of disclosed executives at Halozyme Therapeutics
Helen I. Torley, Chief Executive Officer, received $7.5M in total, which increased by 14% compared to 2020. 54% of Torley's compensation, or $4.1M, was in stock awards. Torley also received $808K in non-equity incentive plan, $1.7M in option awards, $830K in salary, as well as $15K in other compensation.
For fiscal year 2021, the median employee pay was $291,734 at Halozyme Therapeutics. Therefore, the ratio of Helen I. Torley's pay to the median employee pay was 26 to one.
Masaru Matsuda, General Counsel, received a compensation package of $2.8M, which increased by 61% compared to previous year. 38% of the compensation package, or $1.1M, was in stock awards.
Michael J. LaBarre, Senior Vice President, Chief Technical Officer, earned $2.3M in 2021, a 13% increase compared to previous year.
Elaine D. Sun, Chief Financial Officer, received $2.2M in 2021, which decreases by 36% compared to 2020.
Related executives
You may also like
Source: SEC filing on March 25, 2022.